CN106107463A - 超级藜麦抗疲劳奶茶制作工艺 - Google Patents
超级藜麦抗疲劳奶茶制作工艺 Download PDFInfo
- Publication number
- CN106107463A CN106107463A CN201610602552.9A CN201610602552A CN106107463A CN 106107463 A CN106107463 A CN 106107463A CN 201610602552 A CN201610602552 A CN 201610602552A CN 106107463 A CN106107463 A CN 106107463A
- Authority
- CN
- China
- Prior art keywords
- quinoa
- phosphatidylcholine
- effect
- function
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006162 Chenopodium quinoa Species 0.000 title claims abstract description 56
- 235000013336 milk Nutrition 0.000 title claims abstract description 9
- 239000008267 milk Substances 0.000 title claims abstract description 9
- 210000004080 milk Anatomy 0.000 title claims abstract description 9
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 4
- 238000005516 engineering process Methods 0.000 title claims description 9
- 238000012545 processing Methods 0.000 title claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
- 241001441970 Anserinae Species 0.000 claims abstract description 43
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 34
- 235000021119 whey protein Nutrition 0.000 claims abstract description 34
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 33
- 241000169546 Lycium ruthenicum Species 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 12
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 8
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 claims description 6
- 229940055705 pangamic acid Drugs 0.000 claims description 6
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 claims description 6
- 108700024047 pangamic acid Proteins 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 77
- 210000004185 liver Anatomy 0.000 abstract description 21
- 230000002708 enhancing effect Effects 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 206010021143 Hypoxia Diseases 0.000 abstract description 12
- 230000036737 immune function Effects 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 11
- 235000016709 nutrition Nutrition 0.000 abstract description 10
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 9
- 230000035764 nutrition Effects 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 210000002216 heart Anatomy 0.000 abstract description 6
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 208000036654 deficiency anemia Diseases 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- 239000003925 fat Substances 0.000 description 32
- 230000006870 function Effects 0.000 description 29
- 238000011160 research Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 206010016256 fatigue Diseases 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102000004407 Lactalbumin Human genes 0.000 description 6
- 108090000942 Lactalbumin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229960003237 betaine Drugs 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 229960001231 choline Drugs 0.000 description 6
- 230000002124 endocrine Effects 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000003014 reinforcing effect Effects 0.000 description 6
- 206010002660 Anoxia Diseases 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241000976983 Anoxia Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920002414 procyanidin Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 244000308495 Potentilla anserina Species 0.000 description 3
- 235000016594 Potentilla anserina Nutrition 0.000 description 3
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 235000021407 appetite control Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000005693 branched-chain amino acids Chemical class 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- -1 carbon water Compound Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 206010024585 Lipidosis Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000567232 Ochnaceae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001092489 Potentilla Species 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
超级藜麦抗疲劳奶茶属于功能性固体饮品,尤以青藏高原天然无污染优质两用植物藜麦、黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸等原料制成的功能固体饮品。该产品具有滋补肝肾、健脾和胃、养心安神等作用,可提供运动营养和运动能量,能缓解体力疲劳、提高抗缺氧耐受能力、增强免疫功能、抗氧化、改善睡眠和改善营养性贫血、减肥等功能。
Description
一、技术领域:本发明属高级功能固体饮品,尤以青藏高原天然无污染优质药食两用植物藜麦、黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸等原料,采取现代先进工艺加工而成的功能性固体饮品。
二、背景技术:本发明以藜麦、黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸等原料制成的功能性固体饮品。该产品以天然谷物为原料,该产品具有滋补肝肾、健脾和胃、养心安神等作用,可提供运动营养和运动能量,能缓解体力疲劳、提高抗缺氧耐受能力、增强免疫功能、抗氧化、改善睡眠和改善营养性贫血、减肥等功能。目前市场还没有同类产品,创新研发本产品可为给竞技体育和全民健身爱好者提供一种运动营养功能食品。该产品尤以天然无污染的优质谷物为营养制成的新产品,纯度高、生物活性强、吸收利用好、服用方便、无任何毒副作用、效果明显,特别适应于运动领域、军队特种作战领域及国家应激救援领域和全民健身运动、旅游等各种人群服用。
三、发明内容:运动功能营养食品是一类能够针对性的满足运动人体代谢和生理功能需求以及具有高营养素密度和高生物活性的食品,其合理的补充可促进运动人体的健康和运动能力的提高。主要用于调节运动能量、肌肉功能、体能恢复、控制体重等功能。随着我国科技和经济的飞速发展,2008年奥运会在北京的成功举办以及我国全民健身运动蓬勃发展,运动功能营养已经成为运动科学中创新研发的热点,并在竞技体育和全民健身运动中发挥增强体能和保证健康的积极作用。因此,创新研发本产品。
四、原料配方:藜麦20-60千克、黑枸杞(玛咖)提取物1-5千克、乳清蛋白肽(大豆肽)5-10千克、蕨麻粉5-10千克、磷脂酰胆碱1-6千克、潘氨酸0.2-1千克为原料。
五、技术方案:
(一)藜麦(Chenopodium quinoa willd),又叫南美藜,奎麦,金谷子等。原产于美洲安第斯山区,是印加土著居民的主要传统食物,由于具有独特丰富全面的营养价值,养育了印加民族,被称为粮食之母,也可代替婴幼儿奶粉食用。近几年来引进我国青海等地区试种成功,在青藏高原海拔2500实以是柴达木盆地大面积种植。藜麦属藜木科双叶子藜麦的成熟种子。性平味甘,具有全面均衡补充营养,有增强机体功能和增强免疫功能,修复体质,提高机体适应能力、调节内分泌、促进儿童生长发育、预防疾病、美容养颜、减肥、通便、延缓衰老、防癌抗癌、降血压、降血脂、降血糖、防治心脑血管疾病、辅助治疗慢性疾病等功效,也是孕产妇的超级营养食品,被联合国粮农组织认为藜麦是唯一单体植物既满足人体基本营养需求的食物,推荐藜麦为最适宜人类完美的营养食品,并列为全球10大健康营养的“超级谷物”,“未来食品”,以促进人类的健康。尤其适应于高血压、高血脂、高血糖、心脑血管疾病,以及婴幼儿、孕产妇、儿童、老年人等特殊体质等人群,长期食用效果显著。
营养成分:藜麦含有丰富的蛋白质(高达26%,且品质与奶粉和牛肉类相当),碳水化合物、脂肪、多种氨基酸、其中含有人体必需的全部9种氨基酸,比例适当且易吸收,还富含不饱和脂肪酸、类黄酮、β-葡聚糖、胆碱、甜菜碱、α一亚麻酸、矿物质钙、镁、磷、钾、铁、锌、硒、锰、铜等,维生素B族、叶酸、维生素E等化合物,膳食纤维含量高达7.1%,不含胆固醇。
生理功能:1、增强免疫功能:研究发现,藜麦具有增强机体防病抗病能力,调节机体免疫功能的作用,其中藜麦中丰富的蛋白质是构成血红球和抗体的主要成分。实验证明,严重缺乏会使人的免疫细胞中的淋巴球大减,造成严重的免疫机能下降,且易感染疾病。另外,藜麦中含有β-葡萄糖对机体免疫系统有极强的作用,具有活化细胞的功能,防止机体被感染和修复被破坏的组织,同时,藜麦中β-葡萄糖还有激活细胞,提高免疫功能的作用。而藜麦中均衡的营养物质也可通过改善体质提高免疫力。
2、消除疲劳:在体育运动中,通常要消耗能量的4-10%是由蛋白质提供的,藜麦中含有丰富的蛋白质等许多能量成分及易消化吸收,能迅速转化利用,可以抑制或缩短剧烈运动引起的“负氧平衡”,减轻肌蛋白的降解,维持体内正常蛋白质合成,达到快速恢复体力和消除肌肉疲劳的效果。
3、降血脂:藜麦晶及其口服冲剂、藜麦粉对高脂血症和高脂血症家兔血清总胆固醇(TC)、甘油三酯(TG)、β-脂蛋白等均有明显的抑制作用,并能明显升高高密度脂蛋白的胆固醇(HDL-C)水平,其降血脂成分为食物纤维不溶蛋白及脂类等。
4、抗动脉粥样硬化:藜麦粉能明显抑制家兔血脂升高及红细胞胆固醇上升;能明显减轻动脉壁和肝脏脂质沉积,对主动脉内膜不斑块病变的形成有良好的抑制作用。
5、降血糖:研究认为,每天摄入适量的藜麦粉可降低患糖尿病的几率。因为藜麦中含有的钙、镁、维生素和β-葡萄糖可以增强人体合理使用胰岛素的功能。据报道,最新研究发现,经常进食藜麦粉食品,其中含有的脂肪酸可降低患糖尿病的风险,动物实验发现,动物体内存在的脂肪酸可帮助降低胰岛素抵抗性,他们对人体通过对藜麦制品摄入脂肪酸进行调查,研究了3700多名65岁以上老人跟踪调查,结果显示,与进食藜麦制最少的人相比,进食藜麦制品多的人患糖尿病的几率要低63%,同样也可以起到降低胰岛素抵抗作用,从而有效预防糖尿病。
6、减肥:多项研究表明,在摄入热量不变的前提下,饮食中增加藜麦制品的摄入量有助减肥。因为藜麦制品中含有丰富的胆碱和其他一些特殊的活性成分,能帮人体燃烧脂肪,减少脂肪堆积和控制体着有着重要的作用。藜麦制品有助于控制体重的另一因素可能与它含有丰富的蛋白质和膳食纤维能增加人的饱腹感对食欲控制有关,因为蛋白质和膳食纤维能产生较强的饱腹感,延缓胃排空,从而减少其他食物的摄入量来控制食欲,达到减肥的作用。
7、养颜美容:藜麦中含有丰富的蛋白、脂肪类黄酮,多种维生素和多种矿物质等活性成分容易被皮肤吸收,能促进新细胞生长,防止皮肤干燥和老化,使皮肤有光泽湿润,细腻,长期食用还可增加皮肤的活力和弹性,使皮肤变得清爽、润滑、洁白。研究证实,富含蛋白质食物具有补五脏、补虚损、强筋骨、滋润皮肤之功效。维生素和矿物质能使皮肤代谢胜利进行,减少雀斑,黄褐斑和老年斑的产生;脂肪酸具有保水润肤的作用;故均衡的营养能滋养肌肤,抗皱,延缓衰老,防止皮肤老化。
8、防癌抗癌:藜麦中含有多种活性物质,能有效破坏人体内的致癌危险自由基,并能迅速和细胞膜结合,使细胞处于防御致癌物质入浸的状态,因此具有防癌的作用。进一步研究发现,藜麦中的多种营养成份,能使机体内的细胞因子IL-2的含量增加,增强了T细胞和B细胞的功能,提高了NK细胞杀伤活性,使免疫器官的重量和对机体非特异性免疫功能增加的作用,从而达到有效抗癌的作用。
9、调节内分泌:研究表明,藜麦具有调节内分泌的作用。藜麦提取物能促进肾上腺皮质功能和增加肾上腺的重量,使血液中甲状腺素含量增加,因此,藜麦能调节内分泌。
此外,藜麦还具有延缓衰老、防治心脑血管疾病、护眼明目、通便、辅助治疗慢性疾病等作用。
(二)黑枸杞提取物(Lyciam barbarnm extraat),黑枸杞是生长在青藏高原绿色生态环境,纯天然珍品药食两用植物黑枸杞干燥果实。黑枸杞是一种稀有珍贵的原生态高端滋补品。黑枸杞为茄科植物枸杞成熟果实。性平,味甘。归肝、肾经。具有滋补肝肾、益精明目、润肺的功效。用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、提高视力、目昏不明等。现代医学研究认为,黑枸杞具有增强免疫力、抗疲劳、降血压、降血脂、降血糖、保护肝脏、美容祛斑、减肥、抗衰老、抗癌等功能。
化学成分:黑枸杞含多糖、氨基酸、甜菜碱、胡萝卜素、维生素B、维生素C、烟酸等多种维生素以及锰、铬、锌、铜、镁、钙、锗、钴等微量元素。而且还有丰富的天然原花青素,其中原花青素含量是蓝莓含量的数倍,是迄今为止发现原花青素含量最高的天然野生植物。
药理作用:1、增强免疫力:小鼠灌服水提取物或肌注醇提取物均能显著增强其网状内皮系统对印度墨汁的吞噬能力。水提取物或枸杞多糖均能促进小鼠腹腔巨噬细胞吞噬功能和血清中溶菌酶活性。给正常或老年小鼠灌服或腹注枸杞多糖,能显著增强腹腔巨噬细胞c3b和Fc的受体数和活力,可使老年小鼠抑制性T细胞调节抗体功能恢复到成年小鼠的水平。黑枸杞多糖纯品比粗品具有更显著的免疫应答效应,各项免疫指标(包括非特异性免疫的免疫器官质量、巨噬细胞吞噬作用、特异性体液免疫的血清溶血素,特异性细胞免疫中的退发型变态反应、淋巴细胞转化率、E玫瑰花结形成等)均有显著的差异。
2、抗疲劳耐缺氧:黑枸杞提取物可提高羟脯氨酸浓度,从而提高肌力,使抗疲劳能力增加。动物实验表明,黑枸杞提取物可明显延长小鼠负重游泳时间,并可减少小鼠不赠重游泳前、中、后3次血乳酸测定下的面积及游泳后血清尿素氮水平,同时可升高小鼠肝糖原贮备,具有明显的缓解体力疲劳的作外。另外,黑枸杞还能提高小鼠在密封缺氧状态下的存活时间,具有很好的耐缺氧作用。
3、保护肝脏、抗脂肪肝:黑枸杞提取物对保护肝脏和抗脂肪肝具有一定的作用。现代医学研究发现,黑枸杞中含有一种有效成分一甜菜碱,它对治疗肝脏疾病很有效。实验表明,甜菜碱有抑制脂肪在肝细胞内沉积,促进肝细胞再生的作用。另外,黑枸杞的中甜菜碱能防止肝脏内过多的脂肪贮存,有防脂肪肝的作用,据报道,长期经大鼠饲喂水提取物或甜菜碱饲料对ccl4引起的肝损害有保护作用,能明显降低转氨酶及肝中脂质的变化,可抑制肝中脂质沉积及促进肝细胞新生,对肝脏脂质过氧化损伤有明显的保护作用。
4、促进造血,黑枸杞提取物可使正常小鼠骨髓中爆式红系集落形成单位和红系集落形成单位上升;能促进小鼠脾脏T淋巴细胞分泌集落刺激因子,提高小鼠集落刺激活性水平;在体外培养休系中,黑枸杞提取物可加强集落刺激因子的集落刺激活性。还可促进小鼠骨髓造血干细胞的增殖,明显增加骨髓单系细胞数量,促进CFU-GM向粒系分化。
5、消炎抗过敏:组织胺会引起皮肤过敏和红肿,原花青素是一种天然抗组织胺剂,具有优异的抗炎效果,能防止皮肤过敏及日晒后发炎的作用。
6、延缓生殖系统衰老:据国内报道,一项研究成果表明,黑枸杞通过作用“下丘脑-垂体-性腺”轴线,可对被损伤的生殖系统产生作用。实验结果表明,黑枸杞通过促性腺素作用促进垂体分泌性腺激素,对“下丘脑-垂体-性腺”轴线,产生多层调节作用。促进生精过程畅通和睾丸生殖细胞发育。
7、改善性功能:黑枸杞具有补肝肾、生精血、助阳的功能,无论是肾阳虚还是肾阴虚都具有一定作用,黑枸杞提取物还具有促性腺功能的作用,血睾硐水平显著升高,对性功能减退,阳痿有重要的作用。
(三)乳清蛋白肽(Whey Protein)乳清蛋白肽是存于牛奶蛋白质中的混合,经酶解技术制成一类氨基酸组成的比蛋白质分子小,却具有营养和调节生理功能的小分子化合物,也是一类涉及生物体内各种功能的生物活性物质。乳清蛋白肽除了作为高级营养素,可完整的从消化道直接吸收,因此乳清蛋白肽能防治许多疾病,如肥胖、糖尿病、心脑血管病、高血脂、高血压、增强免疯力、抗疲劳、促进生长发育、美容、抗衰老、增强活力、缓解精神压力、亚健康和慢性疲劳综合症等,并对脑动脉硬化、冠状动脉硬化、动脉粥样硬化等均有明显的改善作用。
蛋白质是构成生命最核心的物质,是人类赖以生存的营养素之一。食物中蛋白质不足,将直接导致生长发育及迟缓、身体消瘦矮小、免疫力下降、容易疲劳和生病、创伤恢复迟缓、内分泌失调、皮肤失去光泽并容易老化及贫血等。
生理功能:1、增强免疫力:乳清蛋白肽含有免疫球蛋白乳铁蛋白能调节机体免疫力,增强抗病能力。据报道,乳清蛋白肽富含支链氨基酸,支链氨基酸经过肌肉代谢来制造谷氨酸,进而合成谷胱甘肽,而谷胱甘肽是机体抗氧化防御机制的重要物质,能够直接提高细胞抵抗自由基、污染、病毒、传染病及紫外线的伤害,帮助抵抗疾病,增强免疫力。
2、减肥瘦身:研究表明,乳清蛋白肽具有良好的减肥瘦身功效。不仅能提供机体蛋白质原料和刺激肌肉蛋白合成还能减肥瘦身,因为乳清蛋白肽能够促进脂肪燃烧,即能增肌减肥。据报道,研究人员通过626人14项随机对照临床试验对比试验分析,乳清蛋白肽对体重、体质指数(BMI)、体脂瘦体重(LBM),祛脂体重(FFM)以及腰围测定的对照试验。试验分为两组,其中一组的饮食未发生变化仅仅将乳清蛋白肽作为保健品食用;另一组食用乳清蛋代替其他热量来源,研究结果显示,食用乳清蛋代替其他热量组体重和体脂(下降3.74公斤)显著下降。试验结果表明与糖和其他蛋白质相比,乳清蛋白肽具有明显减肥作用;研究人员分析食用乳清蛋白肽代替饮食中热量的减肥作用发现,相对服用乳清蛋白肽后体重的基准值,研究对像体重平均下降了4.2公斤。另据报道,富含优质蛋白的早餐能够显著控制食欲,也能减少夜间摄入高脂高糖零食,从而保持健康苗条的身材。研究认为,高蛋白食物比富含碳水化合物或脂肪的食物让人产生饱腹感,从而抑制食欲,与那些高碳水化合物和高脂肪的饮食相比,减肥效果更佳。
3、抗疲劳:研究表明,乳清蛋白肽可提高运动成绩和迅速恢复体力,具有显著的抗疲劳作用。研究显示乳清蛋白肽是氨基酸的主要来源,含有支链氨基酸浓度最高的。人在运动期间,整个肌体的蛋白质合成降低,而蛋白质松动变成游离氨基酸,骨骼肌从血液吸收支链氨基酸,并将其分解成葡萄糖以获得能量。因此支链氨基酸在持久性运动中,乳清蛋白肽是他氨基酸没有的独特性,它能提供能量来源,所以具有显著的抗疲劳作用。
4、降血压:据国外报道,研究发现,水解乳清蛋白肽能明显降低血压,其作用机制是乳清蛋白肽可能通过改变血管收缩素转换酵素(ACE)的活性,从而降低血压。
5、抗衰老:乳清蛋白肽是保持人体细胞活性和结构的基本单位,是人体生命活动的核心。乳清蛋白肽还是构成修复细胞、维护细胞活动,供给细胞能量最基本是物质。乳清蛋白肽能维护免疫系统,衰老过程始终伴随免疫功能紊乱,提高免疫功能是对衰老最有效的方法之一。
6、清除自由基:自由基是衰老的罪魁祸首,清除自由基亦是对抗衰老最有效的防治之一。乳清蛋白肽能增强“自由基的排泄系统”。(呼吸系统、消化系统、泌尿系统和皮肤黏膜系统)增强的抗自由基氧化系统超氧化物歧化酶等一些酶的功能,还可增强维生素C,维生素E、还原性谷胱甘肽,胡萝卜素的功能。
7、降低血脂与胆固醇:乳清蛋白肽具有降低血脂和胆固醇的作用。即乳清蛋白肽能增加胆固醇的排出量增多,且降低脂防和胆固醇的吸收,使体内胆固醇沉积降低。另据报道,乳清蛋白肽能阻止肠道内胆固醇的再吸收,并排出体外,防止血清胆固醇升高的作用,从而降低血脂。另外,乳清蛋白肽降低血清胆固醇的还有以下特殊优点:对胆固醇值正常的人没有降低胆固醇的作用,对胆固醇值高的人有降低决胆固醇值的功效,
8、调节血糖:研究表明,乳清蛋白肽对于α-葡萄糖苷酶有缓慢抑制的作用,α-葡萄糖苷酶主要分布在小肠微绒毛上,它的作用是迅速分解糖类以供给体内葡萄糖,因此乳清蛋白肽或与其他碳水化合物,糖类等物混合使用时,不受胰岛素分泌量的影响,能抑制血糖急剧上升的作用。
9、调节肠道功能:乳清蛋白肽能促进肠道内双歧杆菌和乳酸菌的增殖,具有调节肠道功能的作用。
10美容养颜:乳清蛋白肽与皮肤有良好的相触性,有利营养物质的渗透。同时可在皮肤表面形成一种保护膜,使皮肤细腻光滑。研究还发现,经常食用乳清蛋白肽可促进皮下肌肉人的生长,使肌肤丰满而富有弹性,这对防止皮肤松驰,适缓皮肤衰老有良好的作用。
另外,乳清蛋白肽还具有促进生长发育、抗衰老、调节内分泌、美容养颜、增加活力、缓解精神压力、促进伤口愈合及防治贫血等作用。
(四)蕨麻粉(Potentilla anserinal),又名人参果,延寿草。为青藏高原蔷薇科委陵菜属野生植物的块根,藏语中称为“卓老沙僧”,是蔵医常用草药。性温、味甘。具有补益气血、健脾养胃、收敛止血、生津止渴等功效。适用于孕妇、产妇和先天性不足婴儿,脾肾阳虚、病后贫血、营养不良、脾虚腹泻、止咳利痰、吐血、下痢等。现代药理研究表明,蕨麻具有增强免疫力、抗氧化、抗衰老、抗炎、保护心肌、抗菌和抗疲劳等作用,具有较高的医疗和营养价值。
化学成分:含淀粉、蛋白质、18种氨基酸(其中含人体必需的8种氨基酸)、脂肪酸、胆碱、甜菜碱、多糖、黄酮类化合物、有机酸、膳食纤维、多种维生素和矿物质等成分。
药理作用:1、增强免疫力:研究表明蕨麻对机体器官和细胞有很好的保护作用。研究显示,蕨麻水和乙醇提取液具有显著抗氧化可的松所致小鼠胸腺重量降低的作用,对免疫力功能低下小鼠网状内皮细胞的吞噬功能具有明显的激活作用,同时还可抗环磷酰胺所致的迟发型超敏反应抑制,表明蕨麻对机体的非特异性免疫和细胞免疫功能具有增强作用。蕨麻能增强动物巨噬细胞的吞噬功能,并对3月龄小鼠本外抗体形成细胞有明显的促进作用,并对动物的细胞免疫和体液免疫功能均有增强作用。
2、抗疲劳:给小鼠灌服蕨麻提取液连服7天,于末次给药1小时后,将小鼠置于25℃水温中负重游泳试验,结果显示,蕨麻可明显示延长小鼠的游泳时间。
3、耐缺氧:蕨麻乙醇提取物能明显延长常压密闭缺氧小鼠、异丙肾上腺素致心肌损伤小鼠在密闭状态下的存活时间,降低整体耗氧量,并能显著增加减压缺氧状态下小鼠的存活率,有明显的抗氧自由基对红细胞的氧化作用,因此,蕨麻具有明显的耐缺氧作用。
4、保护心肌和神经细胞作用:蕨麻及其提取物对器官缺血再灌注损伤有保护作用,在心肌缺血再灌注方面,主要是蕨麻具有抗氧化、抗炎和保护心肌作用有关。蕨麻提取物可明显起到抗心肌损伤的作用,延长小鼠耐受缺氧的时间,增加机体抗氧化活性。另外研究显示,蕨麻对大脑及神经细胞也有保护作用,可以减轻脑组织氧化应激所造成的损伤。通过实验表明,蕨麻在高原缺氧脑损伤炎症反应中能降低促炎症细胞因子的水平,同时能够升高抗炎细胞因子含量,从而减轻缺氧引起的炎症反应,对神经细胞损伤具有保护作用,且还能够减轻低压缺氧大鼠脑水肿。其机理是通降低促炎症细胞因子含量,升高抗炎症细胞因子含量来实现。
5、安神定志:蕨麻含有铁和镁、钾等元素,能促进血红蛋白的再生,以治疗因贫血造成的心悸、心慌、失眠、健忘。
6、抗应激:动物实验表明,蕨麻提取物能显著延长常压下小鼠的耐缺氧时间,在18-20℃环境中,小鼠耐低温数明显增多;在48℃±1℃温箱中,小鼠耐高温时间比对照组显著延长。
7、促进造血机能:蕨麻对血虚证小鼠灌服,其红细胞、血红蛋白数值于第5天恢复正常,小鼠的血虚证症状明显得到改善,蕨麻对促进造血细胞的生长,并对粒系组细胞的生长有促进作用。
8、健脾养胃:蕨麻常被用来治疗脾胃虚弱、倦怠无力、食欲不振等症状。蕨麻还能够补脾健脾,养胃助消化。藏医药记载,炒蕨麻能补脾健胃、养阴生津、健胃虚弱、健脾止泻、脾胃虚弱、食欲不振、经常腹泻的人可常食蕨麻。另又研究还发现,蕨麻对脾气虚症具有防治作用。结果表明,蕨麻对小鼠细胞免疫有促进作用,对脾气虚症小鼠免疫器官脾脏萎缩有很好的保护作用。另外,蕨麻还可健胃治消化不良。
9、抑制细菌活性:有研究表明,蕨麻具有抑制细菌活性的作用。蕨麻醇提取物对大肠杆菌、枯草芽孢杆菌、蜡样芽孢杆菌、志贺氏菌、金黄色葡萄球菌和沙门氏菌都有一定的抑制作用,而且效果明显。
10、抑制癌细胞:蕨麻具有防治癌细胞增殖和降低癌组织的侵袭性,提高机体抗癌反应能力及对癌细胞的细胞毒作用。动物实验表明,蕨麻对宫颈癌细胞具有显著抑制作用,对其他癌细胞也明显的抑制作用。临床给癌症患者口服蕨麻提取物,是症状得到明显得到改善,还能延长生存期,提高生存质量。
11、抗氧化:研究表明,蕨麻提取物可提高损伤小鼠血清超氧化物岐化酶活力,降低MDA水平,减轻自由基堆积导致的膜脂质过氧化损伤。因此,蕨麻具有很强的抗氧化作用,此作用与其抗自由基的作用有关。
12、补血:蕨麻作为传统藏药其补血作用明显。现代药理研究证实,蕨麻可提高小鼠血液中的红细胞数量,提高血红蛋白含量,具有良好的补血作用。其作用机理可能是促进骨髓造血干细胞繁殖速度,进而促进幼稚红细胞合成血红蛋白。
13、抗衰老:蕨麻抗衰老作用是通过抗氧化和清除自由基作用来实现的。自由基可引起蛋白质氧化,DNA突变、脂质氧化等多种损伤,并通过调节诱导细胞凋亡,蕨麻可抑制ROS诱导的细胞凋亡过程,所以具有显著的抗衰老作用。
(五)磷酯酰胆碱((Phosphatidylcholine)又名磷脂酰胆碱,是由甘油、脂肪酸和胆碱组成的磷脂,是广泛存在于动植物和蛋黄之中的等动植物。磷脂是一类含磷酸根的类脂化合物的总称,是动植物中细胞膜、核膜、质体膜的基本成分和生命的基础物质之一。磷脂分为植物磷脂和动物磷脂。磷脂酰胆碱其结构和人体磷脂相同,具有促进新陈代谢,抗疲劳、促进机体健康、智力发育、增强记忆力、降血脂、护肝、美容养颜、减肥和延缓衰老等功效。
药理功效:1、增强免疫功能:实验表明,磷脂酰胆碱具有明显的促进巨噬细胞吞噬功能的作用,可使巨噬细胞应激性增加,还可增强机体T淋巴细胞DNA的合成,具有显著的免疫功能增强作用。
2、补充机体能量:人体在高强度体力活动中,肌肉细胞依赖磷脂酰胆碱的信息传递和物质传递功能获得所需要的营养和能量,并排除体内代谢物质,在此生理循环过程中磷脂酰胆碱会被大量分解与消耗,只有及时补充足够的磷脂酰胆碱,人体肌肉才能保证持续的能量和营养。这是因为磷脂酰胆碱是构成细胞不可缺少的营养成分之一,磷脂酰胆碱还能有效的增强细胞功能,提高细胞代谢能力,增强细胞消除过氧化物,及时提供人体所需的能量。
3、抗疲劳:科学研究显示,磷脂酰胆碱具有很好的抗疲劳作用。据报道,临床测试,在剧烈的运动中会降低机体血液中磷脂酰胆碱水平,及时补充磷脂酰胆碱,可以预防乳酸聚集,快速恢复正常的心率,以缓解疲劳。测试还表明,磷脂酰胆碱的生物利用度明显优于胆碱氯化物,能使训练后的运动员心率快速下降至正常水平,同时减轻训练后的疲惫感。另外,磷脂酰胆碱还能改善心脏功能以增强体力和耐力,达到消除疲劳的目的。因此,磷脂酰胆碱已成为脑力劳动和体力劳动者的功能性营养物质。
4、提高记忆力:磷脂酰胆碱是构成脑内神经传递物质乙酰胆碱的前体营养剂,是神经元之间传递信息的一种最主要的“神经递质”,当磷脂酰胆碱消化吸收后释放出乙酰胆碱,并随血液循环进入大脑后,随着大脑中酰胆碱含量的增加,大脑神经细胞之间信息传递速度加快,从而起到提高大脑功能,增强记忆力,思维和分析能力。
儿童时期是大脑发育的关键时期,而磷脂酰胆碱是大脑细胞和神经系统不可缺少的营养物质。大脑约含30%磷脂,磷脂酰胆碱的代谢与脑的功能状态有关,补充磷脂酰胆碱可以使儿童注意力集中,促进脑和神经系统发育,使脑突触迅速发达,改善学习,提高学习和认知能力,增强记忆力。
5、防治老年痴呆:大脑的神经传导物(乙酰胆碱)减少,是引起老年疾呆的主要原因,而胆碱是磷脂酰胆碱的基本成分,充足的磷脂酰胆碱为大脑提供信息传导的物质,能有效的防止老年痴呆的发生。
6、防治心脑血管疾病:磷脂酰胆碱分子结构含有亲水性的磷酸脂基团和亲油性的脂肪酸基团,可以使脂类物质与水结合,起到乳化作用,能溶解血液中和血管壁上的脂溶性物质甘油三酯和胆固醇斑块,降低血液黏度,增加血液流动性,使甘油三酯和胆固醇通过新陈代谢排出体外,从而减少脂肪在血管壁上沉积造成的动脉硬化。另外,磷脂酰胆碱富含多不饱和脂肪酸,可以阻断小肠对胆固醇的吸收和促进胆固醇的排泄。同时,磷脂酰胆碱还是高密度脂肪蛋白(HDL)的主要成分,在胆固醇运送、分解、排泄过程中起着“血管清道夫”的作用。大量的医学研究证明,增加人体磷脂酰胆碱的含量,可降低人体胆固醇和甘油三酯,有效地防止动脉粥样硬化及高血脂引起的心脑血管疾病。
7、美容靓发:研究发现,机体如果缺乏磷脂酰胆碱,就会降低皮肤细胞的再生能力,导致皮肤粗糙、皱纹。适量摄入磷脂酰胆碱可以促进皮肤细胞生成,减少皮肤粗糙和皱纹的产生。另外,磷脂酰胆碱具有良好的亲水和亲油性,能使皮肤显得润泽光滑,富有弹性。此外,磷脂酰胆碱所含的肌醇还是毛发的主要营养物质能抵制脱发,使头发慢慢变黑变亮。
8、抗衰老:磷脂酰胆碱能修复损伤的细胞膜、脂蛋白和酶结构等,调整细胞中磷脂与胆固醇的比例,增加磷脂和脂肪酸的不饱和度,有效改善细胞膜的功能,有利于维持血管的年轻化,抗细胞膜老化。果蝇生存实验表明,磷脂酰胆碱能显著延长果蝇的平均寿命和最高寿命。在对小鼠实验发现,磷脂酰胆碱可有效提高心、脑组织中超氧化物歧化酶(SOD)的活性,降低过氧化脂质和脂褐素含量,拮抗过氧化损伤,从而起到抗衰老延寿的作用。
9、促进脂肪代谢、减肥,磷脂酰胆碱是脂肪代谢的活性物质,磷脂酰胆碱中的胆碱影响着脂肪的代谢,能促进脂肪代谢,从而改变人体脂肪的吸收与利用,缩短脂肪在人体内的滞留时间,起到促进脂肪代谢的减肥作用。
10、保护肝脏:磷脂酰胆碱是维持肝脏正常功能的必须营养物质。研究发现磷脂酰胆碱可以保护肝脏不受酒精的侵害,起到解酒的作用,从而有效防止酒精性肝硬化和脂肪肝等疾病的形成。进一步研究发现,磷脂酰胆碱不足是引起脂肪肝的一个重要的原因,脂肪在肝脏内蓄积会破坏肝细胞,易引发肝硬化。磷脂酰胆碱是合成脂蛋白所必需的物质,肝内脂肪则以脂蛋白形式转运到肝外,所以磷脂酰胆碱不但可以防止脂肪肝,而且还能促进肝细胞再生,防止肝硬化和恢复肝功能。
11、调节血脂:磷脂酰胆碱具有显著的降低血液中胆固醇、甘油三酯和低密度脂蛋白的作用,改善高脂血症。磷脂酰胆碱的分子结构中含有亲水的磷酸脂基团和亲油的脂肪酸基团,它可以使脂类物质和水结合在一起,起到乳化作用,能溶解血液中和血管壁上的脂溶性物质甘油三酯和胆固醇斑块,从而减少脂肪在血管壁上沉积,防止动脉硬化。另外研究发现,磷脂酰胆碱富含多不饱和脂肪酸,可以阻断小肠对胆固醇的吸收,促进胆固醇排泄。同时磷脂酰胆碱也是高密度脂蛋白(HDL的主要成分,在胆固醇的运送、分解、排泄过程起着“清道夫”的作用,因此磷脂酰胆碱具有降低血液中胆固醇和甘油三酯的作用,有效防止动脉粥硬化及高血脂引起的心脑血管疾病。
12、控制糖尿病:磷脂酰胆碱缺乏会降低人体胰脏细胞膜活性,使胰脏机能下降,无法分泌充足的胰岛素,不能有效地将血液中的葡萄糖运送到细胞中,会导致糖尿病。适量补充磷脂酰胆碱能明显改善糖尿病症状,很多糖尿病人甚至可不必再注射胰岛素,特别对糖尿病动脉硬化等并发症患者更为有效。
此外,磷脂酰胆碱还具有促进大脑发育,增强记忆,保护心脏健康,化解胆结石、美容、延缓衰老等功能。
综上所述,该产品具有滋补肝肾、健脾和胃、养心安神等作用,可提供运动营养和运动能量,能缓解体力疲劳、提高抗缺氧耐受能力、增强免疫功能、抗氧化、改善睡眠和改善营养性贫血、减肥等功能。
六、制作工艺:
1、原料处理:先将藜麦捡杂,清洗、沥干。
2、浸泡:将清洗后的藜麦加入1:1-5水浸泡8-12小时。
3、磨浆:将浸泡后的藜麦加入1:8-10的水磨成浆液。
4、过滤:将磨好的藜麦浆液送入过滤机,进行过滤。
5、均质浓缩:将过滤后的藜麦浆液加热至60℃,在25MPa下进行均质后浓缩至含固体物40-50%。
6、冷冻干燥:将浓缩后的藜麦浆液送入冷冻室在-40℃--70℃进行冷冻干燥。
7、粉碎过筛:将冷冻干燥后藜麦固体物进行粉碎过80-10目筛(即藜麦速溶粉)。
8、混合搅拌:将藜麦粉与原料配方中剩余的原料黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸混合,充分搅拌均匀。
9、检验包装:将混合后的原料,经检验合格,包装为成品。
七、质量标准:
1、理化指标:
2、服用方法:每日2次,每次30-50克。
3、适用人群:适应于运动领域、军队特种作战领域及国家应激救援领域和全民健身运动、旅游等各种人群服用
八、具体实施方式:
实施例:取藜麦20-60千克、黑枸杞(玛咖)提取物1-5千克、乳清蛋白肽(大豆肽)5-10千克、蕨麻粉5-10千克、磷脂酰胆碱1-6千克、潘氨酸0.2-1千克,经过捡杂、清洗、沥干,加入1:1-5的水浸泡8-12小时后,再加入8-10倍的水磨成浆液,送入过滤机,过滤后将藜麦浆液加热至60℃,在25MPa下进行均质后浓缩至含固体物40-50%,送入冷冻室在-40℃-70℃进行冷冻干燥,干燥后的藜麦固体物进行粉碎后过80-100目筛(即藜麦速溶粉),再与原料配方中剩余的原料黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸混合调配,充分搅拌均匀,经检验合格,包装为成品。
Claims (2)
1.超级藜麦抗疲劳奶茶制作工艺:原料处理、浸泡、磨浆、过滤、均质浓缩、干燥、粉碎过筛、检验包装。
2.工艺特征为:藜麦20-60千克、黑枸杞(玛咖)提取物1-5千克、乳清蛋白肽(大豆肽)5-10千克、蕨麻粉5-10千克、磷脂酰胆碱1-6千克、潘氨酸0.2-1千克,经过捡杂、清洗、沥干,加入1∶1-5的水浸泡8-12小时后,再加入8-10倍的水磨成浆液,送入过滤机,过滤后将藜麦浆液加热至60℃,在25MPa下进行均质后浓缩至含固体物40-50%,送入冷冻室在-40℃-70℃进行冷冻干燥,干燥后的藜麦固体物进行粉碎后过80-100目筛(即藜麦速溶粉),再与原料配方中剩余的原料黑枸杞(玛咖)提取物、乳清蛋白肽(大豆肽)、蕨麻粉、磷脂酰胆碱、潘氨酸混合调配,充分搅拌均匀,经检验合格,包装为成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610602552.9A CN106107463A (zh) | 2016-07-28 | 2016-07-28 | 超级藜麦抗疲劳奶茶制作工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610602552.9A CN106107463A (zh) | 2016-07-28 | 2016-07-28 | 超级藜麦抗疲劳奶茶制作工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106107463A true CN106107463A (zh) | 2016-11-16 |
Family
ID=57290290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610602552.9A Pending CN106107463A (zh) | 2016-07-28 | 2016-07-28 | 超级藜麦抗疲劳奶茶制作工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106107463A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106615107A (zh) * | 2016-12-12 | 2017-05-10 | 山东坤泰生物科技有限公司 | 一种抗心律失常的酸羊奶及其制备方法 |
CN106720371A (zh) * | 2016-11-24 | 2017-05-31 | 鲁智斌 | 一种蕨麻牦牛奶茶及其制备方法 |
CN107439691A (zh) * | 2017-07-14 | 2017-12-08 | 王高兴 | 一种含绿茶或红茶或咖啡或巧克力或玛咖的藜麦矿泉豆奶的制备方法 |
CN108308499A (zh) * | 2018-02-08 | 2018-07-24 | 米盈食品科技(苏州)有限公司 | 藜麦低聚肽蛋白固体饮料及制备方法 |
CN108835264A (zh) * | 2018-06-07 | 2018-11-20 | 苟春虎 | 高级藜麦谷粒营养奶 |
CN108902977A (zh) * | 2018-08-20 | 2018-11-30 | 苟春虎 | 黑藜麦肿瘤愈病康复营养肽 |
CN108967864A (zh) * | 2018-07-05 | 2018-12-11 | 天津益倍元天然产物技术有限公司 | 提高精力、缓解疲劳的功能性组合物及其制备方法和应用 |
CN112075529A (zh) * | 2020-09-15 | 2020-12-15 | 中国食品发酵工业研究院有限公司 | 一种酶解乳清蛋白粉制备抗氧化肽粉的方法及在奶茶粉中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103070239A (zh) * | 2011-10-25 | 2013-05-01 | 北京康比特体育科技股份有限公司 | 一种缓解运动疲劳的乳制品及其制备方法 |
CN105054186A (zh) * | 2015-07-20 | 2015-11-18 | 聊城大学 | 一种藜麦金针菇蛋白饮料及其制备工艺 |
CN105076665A (zh) * | 2015-07-20 | 2015-11-25 | 聊城大学 | 一种藜麦蛋白粉的制备工艺 |
CN105105165A (zh) * | 2015-09-28 | 2015-12-02 | 苟春虎 | 玛咖延春牦牛肉干(片) |
CN105613882A (zh) * | 2016-01-07 | 2016-06-01 | 苟春虎 | 黑青稞降糖茶(奶茶) |
-
2016
- 2016-07-28 CN CN201610602552.9A patent/CN106107463A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103070239A (zh) * | 2011-10-25 | 2013-05-01 | 北京康比特体育科技股份有限公司 | 一种缓解运动疲劳的乳制品及其制备方法 |
CN105054186A (zh) * | 2015-07-20 | 2015-11-18 | 聊城大学 | 一种藜麦金针菇蛋白饮料及其制备工艺 |
CN105076665A (zh) * | 2015-07-20 | 2015-11-25 | 聊城大学 | 一种藜麦蛋白粉的制备工艺 |
CN105105165A (zh) * | 2015-09-28 | 2015-12-02 | 苟春虎 | 玛咖延春牦牛肉干(片) |
CN105613882A (zh) * | 2016-01-07 | 2016-06-01 | 苟春虎 | 黑青稞降糖茶(奶茶) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106720371A (zh) * | 2016-11-24 | 2017-05-31 | 鲁智斌 | 一种蕨麻牦牛奶茶及其制备方法 |
CN106615107A (zh) * | 2016-12-12 | 2017-05-10 | 山东坤泰生物科技有限公司 | 一种抗心律失常的酸羊奶及其制备方法 |
CN107439691A (zh) * | 2017-07-14 | 2017-12-08 | 王高兴 | 一种含绿茶或红茶或咖啡或巧克力或玛咖的藜麦矿泉豆奶的制备方法 |
CN108308499A (zh) * | 2018-02-08 | 2018-07-24 | 米盈食品科技(苏州)有限公司 | 藜麦低聚肽蛋白固体饮料及制备方法 |
CN108835264A (zh) * | 2018-06-07 | 2018-11-20 | 苟春虎 | 高级藜麦谷粒营养奶 |
CN108967864A (zh) * | 2018-07-05 | 2018-12-11 | 天津益倍元天然产物技术有限公司 | 提高精力、缓解疲劳的功能性组合物及其制备方法和应用 |
CN108902977A (zh) * | 2018-08-20 | 2018-11-30 | 苟春虎 | 黑藜麦肿瘤愈病康复营养肽 |
CN112075529A (zh) * | 2020-09-15 | 2020-12-15 | 中国食品发酵工业研究院有限公司 | 一种酶解乳清蛋白粉制备抗氧化肽粉的方法及在奶茶粉中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN101473953B (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN105285952A (zh) | 一种营养均衡的代餐粉及其制备方法 | |
CN105707707A (zh) | 藜麦孕产妇超级营养粉 | |
CN103355544A (zh) | 一种哺乳期母猪饲料 | |
CN102197837B (zh) | 一种沙棘纤维饼干 | |
CN104855994A (zh) | 肾病非全营养配方食品 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN105994748A (zh) | 老青海青稞酥油茶 | |
CN111374312A (zh) | 一种补充全面营养且易吸收的健康食品 | |
CN103704568B (zh) | 临床膳食食品 | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN105249440A (zh) | 一种阿胶糕 | |
CN105380073A (zh) | 一种糖尿病营养餐冲剂 | |
CN106174286A (zh) | 高级金枸杞营养果酱 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
CN102511875A (zh) | 一种适合术后人群饮用的红枣浓浆 | |
CN105166653A (zh) | 一种健胃养生红薯粥产品及其制作方法 | |
CN107712875A (zh) | 黑藜麦减肥代餐 | |
CN106035686A (zh) | 超级藜麦养生植物奶 | |
CN108371709A (zh) | 黑枸杞肿瘤康复基因酶 | |
CN105831735A (zh) | 藜麦婴幼儿超级营养粉 | |
CN107259318A (zh) | 一种营养保健食品 | |
CN107095297A (zh) | 一种营养保健食品 | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161116 |
|
WD01 | Invention patent application deemed withdrawn after publication |